^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Peritoneal Cancer

    1d
    Complete remission induced by immunotherapy in peritoneal carcinomatosis due to colorectal cancer (PubMed, Medicina (B Aires))
    She started combination therapy with ipilimumab and nivolumab, achieving complete metabolic and imaging response as confirmed by PET-CT at 12 months...She started treatment with pembrolizumab, achieving a sustained complete response at 12 months...Both cases illustrate the remarkable clinical benefit of immunotherapy in patients with early peritoneal recurrence of MSI-H/dMMR colon cancer, which is usually associated with poor prognosis. These cases highlight the need to consider the molecular profile in therapeutic planning and reinforce the emerging value of immunotherapy as a cornerstone in the management of these cases.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • PMS2 (PMS1 protein homolog 2)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    1d
    Uncommon Presentation of Primary Bladder Signet Ring Cell Carcinoma With Peritoneal Carcinomatosis: A Rare Case Report. (PubMed, Case Rep Urol)
    Despite peritoneal carcinomatosis, the patient responded to cisplatin/gemcitabine chemotherapy and immunotherapy, demonstrating tumor shrinkage on follow-up imaging. This case highlights the diagnostic challenges of SRCC due to its nonspecific symptoms and potential histological overlap with other metastatic gastrointestinal tumors. Early recognition and a multidisciplinary approach are critical for improving patient outcomes.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CDX2 (Caudal Type Homeobox 2)
    |
    PD-L1 expression • ER negative
    |
    cisplatin • gemcitabine
    2d
    Association of Activating GNAS Mutations and Outcomes with Chemotherapy in Metastatic Appendiceal Adenocarcinoma. (PubMed, Ann Surg Oncol)
    With systemic chemotherapy, GNAS-mutated metastatic/recurrent AAs have worse EFS despite less frequent high-risk features. Routine somatic mutation-testing of patients with AA should be considered for prognostication and possibly therapeutic decision-making.
    Journal
    |
    GNAS (GNAS Complex Locus)
    |
    5-fluorouracil • capecitabine
    2d
    A 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy response. (PubMed, EBioMedicine)
    Our model offers a valuable platform for investigating peritoneal carcinomatosis in HGSOC, with the potential to contribute significantly to developing novel therapeutic approaches.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    3d
    STOPGAP: Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, University of California, Irvine | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    paclitaxel • 5-fluorouracil • leucovorin calcium
    4d
    Gastric-Type Endocervical Adenocarcinoma Mimicking Advanced Ovarian Carcinoma: A Diagnostic Challenge with Carcinomatosis and Obstructive Uropathy. (PubMed, Case Rep Oncol)
    Despite her relatively short symptomatic clinical course, the patient exhibited signs of advanced disease, characterized by peritoneal carcinomatosis, vaginal involvement, and obstructive uropathy from pelvic mass effect. This patient's atypical clinical presentation illustrates that GTEC may mimic ovarian-like tumors, resulting in misclassification and diagnostic delay and further underscoring the challenge that HPV-independent tumors such as GTEC pose to current screening strategies and diagnostic frameworks.
    Journal
    |
    ER (Estrogen receptor)
    6d
    A Single-Arm Prospective Clinical Study of Senaparib as First-Line Maintenance Treatment in HRD-Negative Advanced Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (ChiCTR2600117429)
    P=N/A, N=60, Recruiting, Sun Yat-sen University Cancer Center (Sun Yat-sen University Cancer Hospital, Sun Yat-sen University Cancer Research Institute); Sun Yat-sen Universit
    New trial
    |
    HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HRD
    |
    Paishuning (senaparib)
    6d
    Study on the Correlation Between Mutation Types of BRCA Gene-Positive Epithelial Ovarian Cancer and Clinical Baseline Characteristics, Pathological Features, and Prognosis (ChiCTR2600116755)
    P=N/A, N=80, Not yet recruiting, Linyi Tumor Hospital; Linyi Tumor Hospital
    New trial
    |
    BRCA2 (Breast cancer 2, early onset) • WT1 (WT1 Transcription Factor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    6d
    Intraoperative controlled hypotension reduces intraoperative blood loss during retroperitoneal tumor resection: A randomized controlled study (ChiCTR2500115296)
    P=N/A, N=202, Not yet recruiting, SUN YAT-SEN University Cancer Center; Sun Yat-sen University Cancer Center
    New trial
    6d
    The value of microRNA-mRNA regulatory network in early diagnosis of postoperative intestinal ischemic injury in patients with retroperitoneal tumor (ChiCTR2600116623)
    P=N/A, N=150, Recruiting, Jinshan Hospital,FudanUniversity; Jinshan Hospital affiliated to Fudan University
    New trial
    6d
    A real-world study on the use of Senaparib for first-line maintenance treatment of newly diagnosed BRCAwt advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer (ChiCTR2600117526)
    P4, N=50, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
    New P4 trial
    |
    Paishuning (senaparib)
    6d
    Iparomlimab and tuvonralimab (QL1706) with chemotherapy as neoadjuvant therapy for advanced ovarian cancer, fallopian tube, primary peritoneal cancer with high CD8+ tumor infiltrating lymphocytes (TILs) (ChiCTR2500113846)
    P2, N=35, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    CD8 (cluster of differentiation 8)
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)